Fine-tuned manipulation of the c-MET oncogenic pathway in pancreatic cancer: a new paradigm of personalised medicine.

胰腺癌中 c-MET 致癌途径的微调操作：个性化医疗的新范例。

• 批准号: nhmrc : GNT1162860
• 金额: $ 70.75万
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2019
• 资助国家: 澳大利亚
• 起止时间: 2019-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/fine-tuned-manipulation-personalised-medicine/1379257
• 关键词: Fine; tuned; manipulation; MET; oncogenic

Only 8% of patients with pancreatic cancer (PC) survive the disease, and current therapies, tested in all-comers, have limited success. More than a third of patients with PC may benefit from a novel combination therapy of agents that target cancer cell growth and survival. Significance of our work lies in identifying treatment strategies that can be directed to PC patients in a subgroup-selective manner, ultimately leading to reductions in the mortality associated with this lethal cancer.

只有8%的胰腺癌患者存活下来，目前的治疗方法，在所有患者中测试，效果有限。超过三分之一的PC患者可能受益于一种针对癌细胞生长和存活的新的联合治疗药物。我们工作的意义在于确定可以以亚组选择性的方式针对PC患者的治疗策略，最终降低与这种致命癌症相关的死亡率。